Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1991 3
1992 2
1995 3
1996 5
1997 2
1998 4
1999 5
2000 2
2001 10
2002 7
2003 6
2004 5
2005 2
2006 4
2007 7
2008 6
2009 11
2010 4
2011 3
2012 2
2013 1
2015 3
2016 4
2017 2
2018 1
2019 3
2020 5
2021 10
2022 8
2023 8
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

125 results

Results by year

Filters applied: . Clear all
Page 1
Ulotaront: A TAAR1 Agonist for the Treatment of Schizophrenia.
Heffernan MLR, Herman LW, Brown S, Jones PG, Shao L, Hewitt MC, Campbell JE, Dedic N, Hopkins SC, Koblan KS, Xie L. Heffernan MLR, et al. Among authors: koblan ks. ACS Med Chem Lett. 2021 Dec 6;13(1):92-98. doi: 10.1021/acsmedchemlett.1c00527. eCollection 2022 Jan 13. ACS Med Chem Lett. 2021. PMID: 35047111 Free PMC article.
Ulotaront, a Trace Amine-Associated Receptor 1/Serotonin 5-HT1A Agonist, in Patients With Parkinson Disease Psychosis: A Pilot Study.
Isaacson SH, Goldstein M, Pahwa R, Singer C, Klos K, Pucci M, Zhang Y, Crandall D, Koblan KS, Navia B; Parkinson's Psychosis TAAR1 Study Group. Isaacson SH, et al. Among authors: koblan ks. Neurol Clin Pract. 2023 Aug;13(4):e200175. doi: 10.1212/CPJ.0000000000200175. Epub 2023 May 25. Neurol Clin Pract. 2023. PMID: 37273942 Free PMC article.
Effects of ulotaront on brain circuits of reward, working memory, and emotion processing in healthy volunteers with high or low schizotypy.
Perini F, Nazimek JM, Mckie S, Capitão LP, Scaife J, Pal D, Browning M, Dawson GR, Nishikawa H, Campbell U, Hopkins SC, Loebel A, Elliott R, Harmer CJ, Deakin B, Koblan KS. Perini F, et al. Among authors: koblan ks. Schizophrenia (Heidelb). 2023 Aug 7;9(1):49. doi: 10.1038/s41537-023-00385-6. Schizophrenia (Heidelb). 2023. PMID: 37550314 Free PMC article.
Farnesyltransferase inhibitors: a new class of cancer chemotherapeutics.
Koblan KS, Kohl NE, Omer CA, Anthony NJ, Conner MW, deSolms SJ, Williams TM, Graham SL, Hartman GD, Oliff A, Gibbs JB. Koblan KS, et al. Biochem Soc Trans. 1996 Aug;24(3):688-92. doi: 10.1042/bst0240688. Biochem Soc Trans. 1996. PMID: 8878827 Review. No abstract available.
TAAR1 agonists improve glycemic control, reduce body weight and modulate neurocircuits governing energy balance and feeding.
Dedic N, Wang L, Hajos-Korcsok E, Hecksher-Sørensen J, Roostalu U, Vickers SP, Wu S, Anacker C, Synan C, Jones PG, Milanovic S, Hopkins SC, Bristow LJ, Koblan KS. Dedic N, et al. Among authors: koblan ks. Mol Metab. 2024 Feb;80:101883. doi: 10.1016/j.molmet.2024.101883. Epub 2024 Jan 16. Mol Metab. 2024. PMID: 38237896 Free PMC article.
Farnesyl: proteintransferase inhibitors as agents to inhibit tumor growth.
Omer CA, Anthony NJ, Buser-Doepner CA, Burkhardt AL, deSolms SJ, Dinsmore CJ, Gibbs JB, Hartman GD, Koblan KS, Lobell RB, Oliff A, Williams TM, Kohl NE. Omer CA, et al. Among authors: koblan ks. Biofactors. 1997;6(3):359-66. doi: 10.1002/biof.5520060306. Biofactors. 1997. PMID: 9288406 Review.
125 results